TOP TEN perturbations for 39535_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39535_at
Selected probe(set): 207353_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39535_at (207353_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.8090096
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 9d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.5224543
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

dysferlinopathy study 2 (LGMD2B; severe) / normal vastus lateralis tissue

Relative Expression (log2-ratio):-1.3709021
Number of Samples:2 / 6
Experimental dysferlinopathy study 2 (LGMD2B; severe)
Biopsies of vastus lateralis muscle from male patients with limb-girdle muscular dystrophy 2B (LGMD2B) and severe fibrotic replacement. All subjects showed evidence of a dystrophic process (degeneration/regeneration of muscle fibers) and dysferlin mutation.
Control normal vastus lateralis tissue
Biopsies of vastus lateralis muscle from young adult volunteers. Samples were taken as normal controls from baseline samples of exercise experiments.

sarcoidosis study 6 (orbital adipose tissue) / normal orbital adipose tissue

Relative Expression (log2-ratio):1.2815886
Number of Samples:7 / 22
Experimental sarcoidosis study 6 (orbital adipose tissue)
Orbital adipose tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded.
Control normal orbital adipose tissue
Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded.

oxyphilic adenoma study 1 / normal kidney tissue (fetal)

Relative Expression (log2-ratio):1.2554216
Number of Samples:4 / 2
Experimental oxyphilic adenoma study 1
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control normal kidney tissue (fetal)
Normal fetal kidney tissue samples.

stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.2452116
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 15d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):1.2037382
Number of Samples:8 / 30
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):1.1817417
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)

Relative Expression (log2-ratio):1.1695709
Number of Samples:4 / 2
Experimental renal cell carcinoma study 6 (chromophobe type)
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control normal kidney tissue (fetal)
Normal fetal kidney tissue samples.

expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary) / expO ovary cancer study 1 (adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.1452923
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with endometrioid and clear cell adenocarcinoma.
Control expO ovary cancer study 1 (adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with adenocarcinoma (NOS).